ENDOVASCULAR TREATMENT OF SUPERIOR VENA CAVA SYNDROME: A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.61841/3qrab359Keywords:
Superior vena cava syndome, Endovascular therapyAbstract
Background: Endovascular stenting has been used to manage superior vena cava syndrome for several decades and has become standard firstline practice. Superior vena cava (SVC) syndrome is caused by the obstruction of the SVC and can result in significant morbidity and mortality.
Methods: By comparing itself to the standards set by the Preferred Reporting Items for Systematic Review and MetaAnalysis (PRISMA) 2020, this study was able to show that it met all of cthe requirements. So, the experts were able to make sure that the study was as up-to-date as it was possible to be. For this search approach, publications that came out between 2013 and 2023 were taken into account. Several different online reference sources, like Pubmed and SagePub, were used to do this. It was decided not to take into account review pieces, works that had already been published, or works that were only half done.
Result: In the PubMed database, the results of our search brought up 292 articles, whereas the results of our search on SagePub brought up 315 articles. The results of the search conducted for the last year of 2013 yielded a total 163 articles for PubMed and 127 articles for SagePub. In the end, we compiled a total of 6 papers, 4 of which came from PubMed and 2 of which came from SagePub. We included six research that met the criteria.
Conclusion: In summary, this review confirms the effectiveness of endovascular stenting in managing SVCS. Further directions of research may include specific outcomes of endovascular stenting in benign SVCS, and the impact of procedural characteristics, such as the use of anticoagulation and type of stent used, on outcomes.
References
Friedman T, Quencer KB, Kishore SA, Winokur RS, Madoff DC. Malignant Venous Obstruction: Superior Vena Cava Syndrome and Beyond. Semin Intervent Radiol. 2017;34(4):398–408.
Azizi AH, Shafi I, Shah N, Rosenfield K, Schainfeld R, Sista A, et al. Superior Vena Cava Syndrome. Vol. 13, JACC: Cardiovascular Interventions. Elsevier Inc.; 2020. p. 2896–910.
Fagedet D, Thony F, Timsit JF, Rodiere M, Monnin-Bares V, Ferretti GR, et al. Endovascular treatment of malignant superior vena cava syndrome: results and predictive factors of clinical efficacy. Cardiovasc Intervent Radiol. 2013;36(1):140–9.
Hooker JB, Hawkins BM, Abu-Fadel MS. Endovascular Stenting in 2 Patients with Benign Superior Vena Cava Syndrome. Tex Heart Inst J [Internet]. 2018 [cited 2023 Dec 27];45(4):264–9. Available from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6183629/
Andersen PE, Duvnjak S. Palliative Treatment of Superior Vena Cava Syndrome with Nitinol Stents. Int J Angiol. 2014;23(4):255–62.
Cho Y, Gwon DI, Ko GY, Ko HK, Kim JH, Shin JH, et al. Covered Stent Placement for the Treatment of Malignant Superior Vena Cava Syndrome: Is Unilateral Covered Stenting Safe and Effective? Korean J Radiol. 2014;15(1):87–94.
Haddad MM, Simmons B, McPhail IR, Kalra M, Neisen MJ, Johnson MP. Comparison of Covered Versus Uncovered Stents for Benign Superior Vena Cava (SVC) Obstruction. Cardiovasc Intervent Radiol. 2018;41(5):712–7.
Karakhanian WK, Karakhanian WZ, Belczak SQ. Superior vena cava syndrome: endovascular management. J Vasc Bras. 2019;
McDevitt JL, Goldman GT, Bundy JJ, Hage AN, Jairath NK, Gemmete JJ, et al. Gianturco Z-stent placement for the treatment of chronic central venous occlusive disease: implantation of 208 stents in 137 symptomatic patients. Diagn Interv Radiol. 2021;27(1):72–8.
Irace L, Martinelli O, Gattuso R, Mingoli A. The role of self-expanding vascular stent in superior vena cava syndrome for advanced tumours. Ann R Coll Surg Engl. 2021;103(4):296–301.
Rachapalli V, Boucher LM. Superior vena cava syndrome: role of the interventionalist. Can Assoc Radiol J. 2014;65(2):168–76.
Deshwal H, Ghosh S, Magruder K, Bartholomew JR, Montgomery J, Mehta AC. A review of endovascular stenting for superior vena cava syndrome in fibrosing mediastinitis. Vasc Med. 2020;25(2):174–83.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
